Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
László Gesztesi
Observed names:
L. Gesztesi,
Laszlo Gesztesi
Institution:
National Institute of Oncology
Observed institution:
National Institute of Oncology
ORCID:
0009-0008-2214-8758
Observed ORCID:
0009-0008-2214-8758
OpenAlex ID:
A5044012771
Acute and Late Toxicity after Moderate Hypofractionation with Simultaneous Integrated Boost (SIB) Radiation Therapy for Prostate Cancer. A Single Institution, Prospective Study
2019
·
Kliton Jorgo
, Csaba Polgar
, et al.
·
Pathology & Oncology Research
·
21
PDF
Acute side effects after definitive stereotactic body radiation therapy (SBRT) for patients with clinically localized or locally advanced prostate cancer: a single institution prospective study
2021
·
Kliton Jorgo
, Csaba Polgar
, et al.
·
Radiology and Oncology
·
8
PDF
Reduction of the planning target volume with daily online adaptive radiotherapy in bladder cancer
2025
·
Levente Varga
, Ádám Gáldi
, et al.
·
Strahlentherapie und Onkologie
·
6
PDF
Relationship between biodosimetric parameters and treatment volumes in three types of prostate radiotherapy
2021
·
Zsuzsa S. Kocsis
, Tibor Major
, et al.
·
Scientific Reports
·
6
PDF
Assessment of the predictive power the radiation-induced lymphocyte apoptosis method in prostate cancer patients
2025
·
Gyöngyvér Orsolya Sándor
, Gyöngyi Farkas
, et al.
·
Scientific Reports
·
4
PDF
Alterations of Sexual and Erectile Functions after Brachytherapy for Prostate Cancer Based on Patient-Reported Questionnaires
2024
·
László Gesztesi
, Zsuzsa S. Kocsis
, et al.
·
Prostate Cancer
·
4
PDF
Prostate Cancer Survivors Present Long-Term, Residual Systemic Immune Alterations
2022
·
Katalin Balázs
, Zsuzsa S. Kocsis
, et al.
·
Cancers
·
4
PDF
[Stereotactic body radiation therapy with CyberKnife accelerator for low- and intermediate risk prostate cancer].
2019
·
Kliton Jorgo
, Péter Ágoston
, et al.
·
PubMed
·
4
SP-0350: HDR brachytherapy in one fraction vs LDR brachytherapy in the treatment of localized prostate cancer. Early results
2018
·
P. Agoston
, T. Major
, et al.
·
Radiotherapy and Oncology
·
4
PDF
[Trimodal, organ-preserving treatment of organ-confined, muscle-invasive bladder cancer].
2021
·
Péter Ágoston
, Kliton Jorgo
, et al.
·
PubMed
·
2
[Salvage 125I brachytherapy of locally recurrent prostate cancer].
2014
·
László Gesztesi
, Péter Ágoston
, et al.
·
PubMed
·
2
[The effect of PSMA PET/CT performed in primary staging on the clinical decision].
2025
·
Zsófia Küronya
, Péter Ágoston
, et al.
·
PubMed
·
1
Examining the role of elective pelvic radiotherapy in patients Diagnosed with high- and very High-Risk Non-Metastatic prostate cancer
2025
·
István Nahaji
, Zsuzsa S. Kocsis
, et al.
·
Clinical and Translational Radiation Oncology
·
1
PDF
1592: Dosimetric comparison of adaptive and scheduled plans in adaptive teletherapy of prostate cancer
2024
·
András Herein
, Domonkos Szegedi
, et al.
·
Radiotherapy and Oncology
·
1
Radiotherapy Technique Determines the Magnitude and Persistence of T-Lymphocyte DNA Damage
2026
·
Zsuzsa S. Kocsis
, Péter Ágoston
, et al.
·
Cancers
[Daily online adaptive irradiation of bladder tumors with individualized safety margin creation].
2026
·
Gabriella Dóra Pulugor
, Ádám Gáldi
, et al.
·
PubMed Central
PDF
2344 Long-term outcomes and treatment efficacy in high-risk prostate cancer patients treated with stereotactic extreme hypofractionated radiotherapy
2025
·
Vivien Molnár
, Gábor Stelczer
, et al.
·
Radiotherapy and Oncology
2624 Examining the role of elective pelvic radiotherapy in patients diagnosed with high- and very high-risk nonmetastatic prostate cancer
2025
·
István Nahaji
, Zsuzsa S. Kocsis
, et al.
·
Radiotherapy and Oncology
2803 Comparison of radiotherapy with Cyberknife or low dose rate brachytherapy of low-intermediate risk prostate cancer patients after six-year follow-up
2025
·
Péter Ágoston
, Péter Trauttwein
, et al.
·
Radiotherapy and Oncology
PO-2239 Remaining chromosomal and immunological changes years after prostate cancer brachy- and teletherapy
2023
·
Z. Juranyi
, Z.S. Kocsis
, et al.
·
Radiotherapy and Oncology
PO-1828 Predictive biomarkers, side effects and tumor control in radiotherapy-treated male cancer patients
2022
·
Z. Juranyi
, Z.S. Kocsis
, et al.
·
Radiotherapy and Oncology
Világos sejtes adenocarcinoma férfi húgycsőben. Esetismertetés = Clear cell adenocarcinoma of the male urethra-case report
2021
·
Tamás Weigert
, András Kubik
, et al.
·
Magyar urológia
PDF
PO-1818: Cytogenetic and immunological markers to predict side effects and tumour control in cancer patients
2020
·
Z. Juranyi
, Z. Kocsis S.
, et al.
·
Radiotherapy and Oncology
Show more works
View as search
Works count:
23
Citation count:
68
H-index:
4
I10-index:
1
Year
Topic
Type